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ABSTRACT
An estimated 500 million cases of malaria occur each year. The increasing prevalence of
drug resistant strains of Plasmodium in most malaria endemic areas has significantly reduced the
efficacy of current antimalarial drugs for prophylaxis and treatment of this disease. Therefore,
discovery of new, inexpensive, and effective drugs are urgently needed to combat this disease.
Marine biodiversity is an enormous source of novel chemical entities and has been barely
investigated for antimalarial drug discovery. In an effort to discover novel therapeutics for
malaria, we studied the antimalarial activities of a unique marine-derived peak fraction library
provided by Harbor Branch Oceanographic Institute (HBOI). Within this unique library, we have
screened 2,830 marine natural product (MNP) peak fractions through a medium throughput
screening effort utilizing the SYBR Green-I fluorescence based assay, and have identified 253
fractions that exhibit antimalarial activity. From those inhibiting fractions we have identified
twenty species of marine organisms that inhibit Plasmodium falciparum growth, from which
thirty-five fractions were selected for further study. Among those thirty-five, eighty-three percent
were also found to inhibit the chloroquine resistant strain of P. falciparum, Dd2. The most potent
inhibitors were then screened for their cytotoxic properties using the MTT cell viability assay.
Among the samples that exhibited potent inhibition of P. falciparum growth were fractions
derived from a sponge of the genus Spongosorites sp.. This genus of sponge has been reported to
contain the nortopsentin and topsentin class of bis-indole imidazole alkaloids. Nortopsentin A
inhibited the parasite growth at the trophozoite stage with an IC50 value of 1.6 µM. This is the
first report of antimalarial activity for this class of compound.

iii

I would like to dedicate this work to my family and friends for their support, love, and
encouragement. Thank you for all that you have done for me.

“Discovery consists of seeing what everybody else has seen and thinking what nobody has
thought.” – Albert Szent-Gyorgyi

“Don’t be discouraged by a failure. It can be a positive experience. Failure is, in a sense, the
highway to success, inasmuch as every discovery of what is false leads us to seek earnestly after
what is true, and every fresh experience points out some form of error which we shall afterwards
carefully avoid.” – John Keats

iv

ACKNOWLEDGMENTS
I would like to begin by first expressing my gratitude and thanks to Dr. Debopam
Chakrabarti for his guidance and support throughout my time in the Biotechnology graduate
program. His advice and instruction has been invaluable. I am greatly appreciative of the
opportunities that were available to me as a student working in his lab. The knowledge gained in
his lab will continue to be beneficial throughout my career.
I would like to thank my committee members, Dr. Ratna Chakrabarti, Dr. Henry Daniell,
and Dr. William Self, for their time and guidance throughout this program.
I would also like to thank Dr. Amy Wright at the Harbor Branch Oceanographic Institute
for collaborating with our lab on this project.
Next, I would like to thank the students who worked on the drug discovery project.
Thank you to Lance Radford, Bracken Roberts, Timothy Dillman, and Eric Keasler for all your
help and hard work. You have all been so much help in completing this project, as well as
helping me focus on the important aspects of this research. Without your countless hours spent in
lab, this work would not have been completed in the time that it was done. I truly appreciate each
one of you and your contributions.
I would also like to thank the entire Debopam Chakrabarti lab, both past and present
members. Thank you for your encouragement through the harder moments, and the laughs that
got us through each day. I value each friendship that I have made, and I wish you all the best of
luck in your future endeavors.
Finally, I would like to thank my family for the love and support that they have
shown me, and for helping me succeed in reaching my goals.
v

TABLE OF CONTENTS
LIST OF FIGURES ..................................................................................................................... VII
LIST OF TABLES ........................................................................................................................ IX
CHAPTER ONE: INTRODUCTION ............................................................................................. 1
Malaria Life Cycle ...................................................................................................................... 2
Disease Prevention Approaches .................................................................................................. 6
Available Malaria Therapeutics .................................................................................................. 7
Quinolines ............................................................................................................................... 7
Antifolates ............................................................................................................................. 10
Artemisinin ........................................................................................................................... 14
Antimalarial Drug Development............................................................................................... 18
Marine Natural Products ........................................................................................................... 22
CHAPTER TWO: MATERIALS AND METHODS ................................................................... 26
HBOI Peak Fraction Library ..................................................................................................... 26
P. falciparum Culture................................................................................................................ 26
P. falciparum Synchronization ................................................................................................. 27
Hypoxanthine Incorporation Assay .......................................................................................... 27
SYBR Green-I Fluorescence Assay .......................................................................................... 28
Assay Accuracy and Sensitivity................................................................................................ 28
Mammalian Cell Toxicity Assay .............................................................................................. 29
CHAPTER THREE: SCREENING OF HBOI PEAK FRACTION LIBRARY .......................... 31
Validation of SYBR Green-I Fluorescence based assay........................................................... 32
Primary Screening of Marine Natural Products ........................................................................ 32
Screening of Peak Fractions against Drug Resistant P. falciparum ......................................... 38
CHAPTER FOUR: MTT CELL VIABILITY ASSAY ................................................................ 42
HBOI Peak Fraction Library Selected Fractions ...................................................................... 43
CHAPTER FIVE: NORTOPSENTIN A AS A NOVEL ANTIMALARIAL .............................. 46
Nortopsentin A inhibition of Plasmodium falciparum growth ................................................. 46
Nortopsentin A Cell Viability Assay ........................................................................................ 46
Effect of Nortopsentin A on Parasite Development ................................................................. 51
CHAPTER SIX: DISCUSSION ................................................................................................... 53
REFERENCES ............................................................................................................................. 56
vi

LIST OF FIGURES
Figure 1 Plasmodium life cycle (Wells, Alonso et al. 2009). ......................................................... 5
Figure 2 Folate biosynthetic pathway (Gregson and Plowe 2005). .............................................. 13
Figure 3 Antimalarial compound chemical structures (Wells, Alonso et al. 2009). ..................... 17
Figure 4 Molecular Targets for antimalarial drug discovery (Wells, Alonso et al. 2009). ........... 21
Figure 5 Distribution of Organisms in the HBOI Repository by Phylum or Division (Wright
2000) ............................................................................................................................................. 25
Figure 6 Dose-response curves were used to evaluate the IC50 value of preliminary hits. Percent
parasitemia was determined by the comparison of parasite growth in treated parasites versus
those treated with 1 M chloroquine, and those that remained untreated. ................................... 37
Figure 7 Dose-response curves were used to evaluate the potency of preliminary hits against
chloroquine resistant parasites. Percent parasitemia was determined by the comparison of
parasite growth in treated parasites versus those treated with 1 M artemisinin, and those that
remained untreated. ....................................................................................................................... 41
Figure 8 Toxicity profiles of select MNPs exhibit promising selectivity indices. Prediction of in
vivo selectivity index was performed by comparison of inhibition in the presence of selected
peak fractions compared to cells that were untreated and those that were treated with digitonin.
Peak fractions that had a selectivity index greater than 10 were determined to be promising for
future studies. ................................................................................................................................ 45
Figure 9 Chemical structure for Nortopsentin A. ......................................................................... 48
Figure 10 Inhibition of chloroquine sensitive and chloroquine resistant parasite growth by
Nortopsentin A. Dose-dependent inhibition was performed beginning at 10 M concentration
and decreasing to 0.2 M. The assay was performed using the 1 M concentrations of
chloroquine and artemisinin as positive controls. ......................................................................... 49
Figure 11 Toxicity in the presence of Nortopsentin A. Toxicity was evaluated at concentrations
of 0.5X, 1X, 10X, 100X, and 200X of the parasite IC50 value, using the absence of drug
treatment and digitonin treatment as positive and negative controls. ........................................... 50
Figure 12 Development of chloroquine sensitive parasites in the presence of 3 M Nortopsentin
A. Images of the parasite culture were taken at 0 hours, 16 hours, 32 hours, and 48 hours. The
vii

stage of growth was observed in both treated and untreated cells to determine the effect of
Nortopsentin A on parasite development. ..................................................................................... 52

viii

LIST OF TABLES
Table 1 The number of peak fractions inhibiting chloroquine sensitive 3D7 growth. Each fraction
that was identified as a preliminary hit based on the percent inhibition compared to 1 M
chloroquine. .................................................................................................................................. 34
Table 2 Inhibiting peak fractions from plates Mal004 through Mal011. Inhibition was measured
in comparison with the inhibition of parasite growth by 1 M chloroquine in chloroquine
sensitive parasites.......................................................................................................................... 35
Table 3 IC50 values of inhibiting peak fractions in 3D7. The IC50 values for the preliminary hits
were determined using the SG assay with 1 M chloroquine as a control for parasite growth
inhibition. ...................................................................................................................................... 36
Table 4 Inhibition of chloroquine resistant parasites. A Dd2 parasite cell line was used to screen
the preliminary hits for their ability to inhibit compared to 1 M artemisinin. Inhibition of Dd2
percent inhibition was then compared to 3D7 percent inhibition to predict which fractions had
the potential to work in resistant strains of the parasite. ............................................................... 39
Table 5 IC50 values of inhibiting peak fractions in Dd2. The IC50 values were determined using
the SG assay with 1 M artemisinin as a control for inhibition of chloroquine resistant parasite
growth. .......................................................................................................................................... 40

ix

CHAPTER ONE: INTRODUCTION
Malaria is one of the most deadly parasitic diseases in the world. Over 41% of the
world’s population live in endemic areas, and according to the 2009 World Health Malaria
Report, an estimated 500 million cases of infection and over 1 million deaths occur each year
(WHO 2009). This number although alarmingly high, does not even include the large number of
unreported cases that occur each year (Snow, Guerra et al. 2005). Susceptibility is not limited to
a certain population of individuals, but the most severe cases of infection and mortality are seen
in pregnant women and children under the age of five, due to the inability of these individuals to
effectively fight off infection. Worldwide increases of malaria infection and mortality are
associated with an increase in drug resistant parasites Many of these infections occur in subSaharan Africa where the incidence of drug resistant parasites is consistently rising, while the
development of novel therapies has not (Eastman and Fidock 2009).
Pharmaceutical companies are perpetually looking to increase profits by discovering their
next “blockbuster” drug. Research is most often times directed towards diseases that concern the
consumers living within developed countries, and include areas such as cancer, cardiovascular
diseases, and AIDS (Frearson, Wyatt et al. 2007). While these diseases result in a high mortality
rate in developed countries, some of the world’s most fatal diseases, mostly infectious diseases,
are being neglected because of the poor economic state of the affected countries. Parasitic
diseases such as leishmaniasis, trypanosomiasis, giardiasis, and malaria result in millions of
deaths worldwide and have an enormous global impact, yet most of the drugs used to treat these
diseases are over 30 years old and no longer effective (Renslo and McKerrow 2006). As of 2001,
malaria infections were ranked the eighth highest contributor to the global Disability Adjusted
Life Year (DALY) and second in highest contributor in Africa (Snow, Newton et al. 2003).
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Parasitic diseases are prevalent in countries where patients do not have access to adequate health
care, and are unable to pay for expensive therapies. This results in many patients waiting to seek
therapy until the onset of severe symptoms (Frearson, Wyatt et al. 2007). There is an urgent need
for inexpensive, effective, and safe drugs to combat these diseases, and within the past ten years
there has been an increasing effort in parasitic drug discovery. This is mostly due to government
agencies, like World Health Organization (WHO) and philanthropies, such as the Gates
Foundation and Medicines for Malaria Venture (MMV). Yet, even with these organizations and
the money that has been donated to identify new drugs and vaccines, we are still a long way from
finding a cure, and better options for treatment.
Although malaria drug discovery research will primarily benefit developing nations, it is
important to remember that even citizens of the developed world could be at potential risk.
Because individuals of developed nations have more opportunities to travel for business and
pleasure, the potential risk for infection among travelers could become a problem. Many of the
military personnel are also at risk for acquiring malaria overseas while on duty. Even though the
US number of infections and transmission rates are low, infection is still possible (Milhous and
Kyle 1998; Snow, Guerra et al. 2005).
Malaria Life Cycle
An understanding of the parasite developmental cycle is critical to the design and
development of novel therapies against infection. The majority of severe malaria cases that occur
are due to infection by the parasite Plasmodium falciparum, which is the most deadly species of
Plasmodium in humans. Four other species can also infect humans, P. vivax, P. ovale, P.
malariae, and P. knowlesi. Although P. knowlesi was thought to be a simian malaria parasite,
human infections have recently been reported in Thailand and Singapore (Jongwutiwes,
2

Putaporntip et al. 2004; Ng, Ooi et al. 2008).Overall, the life cycle stages of these species are
quite similar with the parasites having three distinct stages during their life cycle, two asexual
stages, and one sexual stage of development, Figure 1. Infection of a vertebrate host begins by
the injection of sporozoites, an asexual form of the parasite, into the host when an infected
female Anopheles mosquito takes her blood meal. If the parasites are able to overcome the
barriers mounted by the host’s immune response to infection, they travel to the liver through the
blood stream and cross the sinusoidal layer and basement membrane to infect the hepatocytes
(Beier and Vanderberg 1998) . Once inside the hepatocytes, the parasite forms merosomes,
which are aggregates of merozoites. An exception is the infection caused by P. vivax and P.
ovale that are able to remain dormant in the liver as hypnozoites for extended periods of time.
When the merosomes rupture, they release thousands of merozoites that travel through the blood
stream to invade erythrocytes; this begins the asexual, developmental stages of the parasite
(Beier and Vanderberg 1998).
During the developmental stages of Plasmodium, the parasite undergoes multiple DNA
replication cycles. In the case of P. falciparum, this occurs once every 48 hours. The parasite
first invades the erythrocyte as a merozoite, where it forms a ring-like structure, named so
because of the shape it portrays on a Giemsa stain. At this stage, the parasite begins to increase in
size, creating a suitable environment for its growth and survival within the erythrocyte (Ayong,
Pagnotti et al. 2007). DNA replication and synthesis then begins in the proceeding trophozoite
stage. The transition from the trophozoite form to schizont stage is difficult to pinpoint, because
the increase of DNA content continues throughout the schizont stage (Grimberg, Jaworska et al.
2009). Later, the formation of multinucleated schizonts appears in the RBC. This multinucleated
form is often referred to as a segmented schizont, which then ruptures and releases merozoites
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into the blood where new infections can take place. In order for the parasite to infect other hosts,
it must be taken up by the mosquito and injected once again.
The formation of gametocytes is simultaneously occurring during the developmental
cycle. In P. falciparum, the development of macrogametocytes and microgametocytes, female
and male, respectively, form as a result of both environmental and innate triggers (Sinden 1998).
The fertilized zygote is taken up during the blood meal of the female Anopheles mosquito. After
a 12-24 hour period the development into ookinetes occurs, which is followed by invasion of the
mosquito’s mid-gut epithelium (Sinden 1998). Once the ookinete is present in the mid-gut basal
lamina, it develops into the oocyst, which is surrounded by a capsule, and undergoes a series of
nuclear divisions to form sporozoites. These sporozoites mature and subsequently invade the
salivary glands of the mosquito, where they are ready for re-injection into a new host and reinitiating the parasite transmission cycle (Sinden 1998).

4

Figure 1 Plasmodium life cycle (Wells, Alonso et al. 2009).
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Disease Prevention Approaches
During the 1950s and 1960s there was a movement to eradicate malaria through the
Global Malaria Eradication program. This goal was carried out by administering chloroquine and
pyrimethamine as well as spraying of DDT to eliminate the parasite vectors (Talisuna, Bloland et
al. 2004). Since the end of the Global Malaria Eradication Program in the early 1970s, due to the
increase in resistance and lack of structured health care systems, there has been a need to find
more effective ways of treating and preventing Plasmodium infection (Wright, Fritz et al. 1972).
An effective method currently used for prevention includes the use of special bed nets that
contain pyrethroid insecticides. These bed nets are able to kill the Anopheles mosquito vectors
that carry the parasite thus preventing transmission of infection. Resistance to these insecticides
is a concern in many areas where bed nets are currently in use. Research efforts to find new and
effective insecticides are ongoing (Greenwood, Fidock et al. 2008). It is apparent that although
these nets serve as an excellent first line of defense against infection, development of effective
preventative and/or therapeutic approaches are needed to control the spread of disease.
Development of an effective vaccine would be an ideal means for malaria prevention.
The most promising vaccine candidate is currently in phase III clinical trials. Glaxo-Smith
Kline’s RTS,S vaccine targets the pre-erythrocytic stage of P. falciparum (GlaxoSmithKline
2010). During this stage, there are many barriers, like the activation of cytotoxic lymphocytes,
which the parasite must overcome in order to efficiently invade hepatocytes. The limited amount
of sporozoites present within the human host during this stage also makes it an attractive vaccine
target (Greenwood, Fidock et al. 2008). Live attenuated vaccines were created in the 1950s and
1960s that were lacking essential liver stage proteins, 6-cysteine proteins and parasitophorous
vacuole (PV) deficient protein. Both of these proteins are required for the formation of the PV,
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an environment that shields the parasite from the host immune response. Symptoms associated
with uncomplicated malaria infection, which include fever, nausea, headaches, and chills, occur
during the developmental stage of the parasite, for which natural immunity is acquired
throughout an individual’s lifetime (Greenwood, Fidock et al. 2008; Pierce and Miller 2009).
Mimicking the naturally acquired immunity can potentially result in a vaccine that prevents the
onset of severe disease in younger patients (Pierce and Miller 2009). Other promising vaccine
candidates include those that protect against placental malaria which affects women who are
most often having their first or second child (Pierce and Miller 2009). Studies on antibodies
which block the adhesion of P. falciparum parasites to the placental receptor, chodroitin sulfate
A, have been shown to result in higher birth weights and longer gestational periods, and could
result in an effective vaccination during pregnancy (Duffy and Fried 2003). Identification of an
effective vaccine would result in a decrease in the transmission rate of infection, and reduce the
need for novel therapies. But the success for malaria vaccine discovery has been limited, and
until a vaccine can be safely administered to all individuals within affected regions, there will
continue to be a growing need to discover and understand novel antimalarials.
Available Malaria Therapeutics
Quinolines
One of the most potent antimalarials to date is quinine, which has been used in many
forms since the earliest reports of malaria in the world. Quinine is a naturally occurring chemical
compound found in the bark of cinchona trees, and throughout its use, it was identified as a
chemotherapeutic for the treatment of malaria (Meshnick 1998; Desowitz 1999). Quinine is not
preventative, and was only used once the symptoms of disease began to occur. Since its
discovery, several derivatives of the compound have been developed with increased potency
7

against malaria parasites. One of the first compounds synthesized was chloroquine, a 4aminoquinoline, but due to inaccurate reports of toxicity, the drug was not used until the mid
1940s. During this time, the United States Military studied its structure and re-examined its
toxicity, ultimately leading to the determination that it was a safe drug for prophylactic and
chemotherapeutic use (Desowitz 1999).
For the past 50 years, chloroquine has been the gold standard for treatment of malaria
infection for all four Plasmodium species. The use of chloroquine over many other
chemotherapeutics in the past has been attributed to its effectiveness, as well as the safety of the
drug for pregnant women and children (Nwaka and Hudson 2006). Because of its widespread
use, the efficacy of the drug began to decline with the emergence of chloroquine drug-resistant
strains. Reports of resistance first appeared in 1957 along the Thai-Cambodia border and then
spread throughout Thailand by 1960. Another, foci of resistance emerged in 1960 in Colombia,
while African countries began to see resistance in the mid-1970s (Talisuna, Bloland et al. 2004).
Since then, chloroquine resistant strains of P. falciparum have been documented in every country
that is affected by malaria infections (Fidock, Rosenthal et al. 2004).
Chloroquine’s mechanism of action is still being studied for a more in depth
understanding of the parasite biology, and although some debate over the topic remains, it is
apparent that chloroquine is involved in disrupting the processes of the digestive vacuole. The
digestive vacuole utilizes aspartic and cysteine proteases to degrade hemoglobin and obtain
amino acids for protein synthesis. This process is the most active during the late ring and
trophozoite stage of the parasite, and it has been suggested that chloroquine acts by inhibiting
these activities (Gluzman, Francis et al. 1994; Francis, Sullivan et al. 1997; Krogstad and
Dibyendu 1998).Chloroquine has been hypothesized to act on the food vacuole in a few different

8

ways. During the degradation of hemoglobin, the free heme that accumulates, as a result, is
membrane toxic to parasite and the RBC. In order to overcome this, the parasite binds the heme
into a non-toxic form called hemozoin. Chloroquine is thought to bind to free heme present after
hemoglobin degradation. This heme is then no longer able to be bound into a non-toxic form, and
kills the parasite. Understanding the mechanism of action for a drug is most often thought to be a
starting point for also understanding its mechanism of resistance. In the case of chloroquine, the
factors related to both mechanisms are associated with the digestive vacuole, but how they act on
the parasite are unrelated, and have required researchers to develop an understanding of resistant
parasites.
Chloroquine resistance is a major problem within endemic countries, and there have been
many efforts to reduce and reverse the occurrence of resistant strains of P. falciparum. The
mechanism of chloroquine resistance within the parasite has been shown to occur due to multiple
mutations within the chloroquine resistant gene, Pfcrt. This gene is responsible for producing the
PfCRT transporter that localizes to the digestive vacuole and causes an efflux of chloroquine out
of the digestive vacuole where the drug acts (Wellems and Plowe 2001). Verapamil is a calcium
channel blocker that is sometimes prescribed for patients with irregular heartbeats and high
blood pressure. It works by relaxing blood vessels in order to allow the blood to flow more easily
to the heart (MedlinePlus 2010). It has been shown that verapamil increases the accumulation of
chloroquine within resistant parasites. The increased accumulation was only seen in resistant
strains of the Plasmodium, and has therefore led researchers to hypothesize that the occurrence
of resistant parasites is related to calcium transport. Another suggested mechanism of resistance
is a change in pH within the digestive vacuole. Chloroquine is a weak base and is localized to
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this acidic compartment where it presumably inhibits the ability of the drug to effectively kill the
parasite (Reeves, Liebelt et al. 2006).
In order to overcome the problem of chloroquine resistance, a series of chloroquine
analogs were synthesized. One of the first attempts aimed at synthesizing new drugs was the
combination of two quinoline structures attached by a linker. The side chains of this structure
were modified in order to create a series of related chemical compounds. One of the more
promising chemical entities was mefloquine, which was introduced as an antimalarial in 1975
(Raynes 1999). Mefloquine’s mechanism of action appears to be similar to that of chloroquine,
in that it interferes with the food vacuole’s degradation of hemoglobin. Although mefloquine was
initially active against chloroquine resistant parasites, an increase in mefloquine resistant
parasites has occurred since its introduction. Primaquine is another quinoline based drug, 8aminoquinoline that was synthesized as a second generation drug and was used to combat drug
resistant P. falciparum parasites. It has also been found that it effectively prevents relapse
infections from occurring in patients infected with P. vivax by killing dormant hypnozoite liver
stage parasites (Wells, Alonso et al. 2009). Quinine and its derivatives were at one time effective
at treating Plasmodium infection, but due to the emergence of resistant parasites this form of
treatment is no longer effective at clearing infection. The need to identify novel chemical
structures and compounds that are potent against P. falciparum, as well as targeting different
cellular targets, has led to the development of other well known antimalarials.
Antifolates
Antifolates are agents that inhibit folate synthesis in the malaria parasite. The folate
synthetic pathway in P. falciparum has been suggested to be mediated by a de novo pathway in
which the parasite synthesizes folate for the reduction of GTP into tetrahydrofolate (Ferone
10

1977); however as a salvage pathway for folate synthesis has also been identified, it is most
likely not the main source of folate (Gregson and Plowe 2005). Tetrahydrofolate is necessary for
the metabolism of amino acids, nucleic acids, and L-glutamate for the parasite’s continuation
through its cell cycle (Cowman 1998). Inhibitors of this pathway eventually halt DNA synthesis
and kill the parasite.
There are many enzymes involved in the folate synthetic pathway (Figure 2), and there
are two that are the targets for antifolate drugs used as chemotherapies for the treatment of
malaria. The first enzyme within the pathway, which has been shown to be inhibited by
Sulfadoxine is dihydropteroate synthase (DHPS). This enzyme works by inhibiting the
enzymatic activity of DHPS to condense p-aminobenzoic acid (PABA) along with 6hydroxymethyl-7,8-hihydropterin pyrophosphate to yield 7,8-dihydropteroate substrate for
subsequent dihydrofolate synthesis. Sulfadoxine is structurally similar to PABA and interferes
with the condensation reactions, thus halting the folate synthesis pathway and killing the parasite
(Fidock, Su et al. 1999).
Other antifolates have also been identified for their therapeutic and prophylactic
properties against malaria. These include marketed antimalarials which inhibit the enzyme
dihydrofolate reductase (DHFR), like pyrimethamine, cycloguanil and their derivatives. Both
pyrimethamine and cycloguanil are structurally similar to folate and inhibit the ability of DHFR
to reduce dihydrofolate to tetrafolate (Fidock, Su et al. 1999; Gregson and Plowe 2005).
Clinically, Sulfadoxine is used in combination with pyrimethamine to prevent infraction as well
as treat patients who have acquired infection by chloroquine resistant parasites. The combination
of these drugs is marketed as Fansidar, and is relatively inexpensive, or at least comparable in
price to chloroquine (Cowman 1998).
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Since the 1940s, antifolates have been available to treat malaria, but due to the high
reports of drug resistance and the slower rate of parasite death, chloroquine remained a more
attractive choice for therapy. One of the major problems with antifolates is that when used as a
mono-therapy, there is a rapid development of resistant P. falciparum strains. But, a study in
1959 found that when pyrimethamine and sulfadoxine were combined, the combination was
more effective than chloroquine alone; however. resistant parasites were found to develop after
long periods of treatment (Gregson and Plowe 2005). This resistant phenotype has been analyzed
using laboratory strains of the parasites, and it has been shown that DHFR inhibitors are no
longer effective when a series of point mutations at positions 16, 50, 51, 59, 108, and 164 in the
Pfdhfr gene occur (Gregson and Plowe 2005). These mutations occur within the active site of the
enzyme’s catalytic pocket. Mutations in the gene, coding for the DHPS enzyme also occurs in
drug resistant parasites. One of the explanations for the occurrence of these mutations is that
sulfadoxine and pyrimethamine are not rapidly cleared from the body. This allows for the
selection of resistant parasites over time. Modifications to both sulfadoxine and proguanil have
yielded a new class of antifolates, chloroproguanil and dapsone that are cleared more rapidly
from the body, and were once a considered to be a promising therapy which would have a rate of
resistance development (Hyde, Dittrich et al. 2008). During phase III clinical trials of the drug
combination, it was shown that there was a significant amount of hemoglobin degradation that
occurred in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. Because ten to
twenty-five percent of the sub-Saharan population possessing this deficiency, this new class of
antimalarials would have done more harm than good (GlaxoSmithKline 2008). Other
antimalarials have also been developed and offer potency as well as a lower risk of negative side
effects.
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Figure 2 Folate biosynthetic pathway (Gregson and Plowe 2005).
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Artemisinin
Artemisinin, also known as qinhao, is a natural product derived from the Chinese
herbal medicine from Artemesia annua, and has been found to be a potent antimalarial against
chloroquine resistant and antifolate resistant drugs (Meshnick 1998). While discovery of
artemisinin was a major advancement in the search for novel antimalarials, there are some
problems associated with the use of artemisinin and its derivatives as a first line of defense
against P. falciparum infections. The first is in the method of production for artemesinin. In
order to make large quantities of artemesinin, it must first be extracted from the plant and then
modified into its derivative forms, dihydroartemisinin, artemether, arteether, and artesunate
(Eastman and Fidock 2009). The length of time and labor required to produce the semisynthetic
derivatives makes the cost of artemisinin more expensive than the other antimalarials currently
being used (Lubell, Yeung et al. 2009). The recent demonstration that the precursor for the
production of artemisinin could be produced in genetically engineered yeast, Saccharomyces
cerevisiae generates the hope that issues related to the availability of artemisinin can be
overcome through biotechnology (Ro, Paradise et al. 2006).
Although progress has been made to reduce the production cost of artemisinin based
drugs, there have been concerns about its toxicity. Artemisinin has been shown to cause
neurotoxicity and embryo lethality in animal models (Gregson and Plowe 2005). Clinical studies
that have been performed with children and pregnant women have not yielded similar results
(Eastman and Fidock 2009). The concerns for the possible side effects of artemisinin indicate a
need for a more thorough understanding of how the drug targets the Plasmodium parasite.
Although the exact mechanism of action of artemisinin is not known, recent discoveries
show that artemisinin locates to the digestive vacuole and may somehow affect heme and iron
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within the parasite as well as potentially causing an increase in free radicals (Meshnick 1998;
Eastman and Fidock 2009). In order to further determine the mechanism of action, studies have
successfully shown that the peroxide bridge within the heme iron is reduced within the digestive
vacuole. The generation of free radicals in the presence of artemisinin has been thought to
alkylate and oxidize lipids and other proteins within P. falciparum, and could potentially lead to
parasite death (Eastman and Fidock 2009). This information is critical to the understanding of
the parasite’s death and the possible mechanism of resistance.
The rate at which the development of resistance occurs is a major concern as with any
new antimalarial drug, and it is important to determine the mechanism by which this might
occur. Because artemisinin has a short half life, and does not remain in the body for extended
periods of time at low concentrations, resistance in clinical isolates is not as likely to occur as
compared to other antimalarials with longer half lives. In order to better understand a potential
resistance mechanism, parasites were placed under selective pressure to isolate resistant lines
with mutations (Witkowski, Lelievre et al. 2010). Some studies have shown data indicating that
mutations associated with the pfatp6 and pfmdr1 genes occur within parasites that are less
sensitive to artemisinin. PfATP6 is a calcium dependent ATPase found within the endoplasmic
reticulum, and PfMDR1 is a multidrug resistance protein 1(Eastman and Fidock 2009). One of
the therapeutic approaches to circumvent the possible rise of resistant parasites has been the use
of an artemisinin regime that is combined with other antimalarials. Over the past few years,
artemisinin combination therapies (ACTs) have become the first line of treatment for patients
with malaria.
ACTs are combinations of artemisinin derivatives, artenmol, artmether, arteether,
artesunate, and DHA, with other known antimalarials, such as sulfadoxine and mefloquine,
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whose structures are shown in figure 3. The efficacy of this combination is evident in the success
in treating patients without an increase in drug resistance. Although some reports have indicated
a potential decrease in sensitivity to artemisinin in patients who have undergone therapy, the
clinical isolates were tested in culture and are still susceptible to artemisinin treatment
(Witkowski, Lelievre et al. 2010). The success of ACTs is a major breakthrough for antimalarial
development, but evidence has shown that resistant parasites can arise, and with the cost
associated with artemisinin treatment as well as potential negative side effects, there is still a
need for novel, inexpensive, and safe antimalarials.
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Figure 3 Antimalarial compound chemical structures (Wells, Alonso et al. 2009).
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Antimalarial Drug Development
The past five years has seen an increased effort in antimalarial drug development due to
an increase in the number of partnerships that have been formed between the pharmaceutical
industry, academia, and government institutions. These partnerships are beneficial in that much
of the discovery phase of research is performed in an academic setting, which reduces the cost of
development for pharmaceutical companies. Once a compound, or series of compounds, is
identified, the pharmaceutical company can become involved in the development of the
compound into a potentially marketable drug. Through these key partnerships, the pipeline for
new antimalarials has increased over time to the portfolio that now includes a number of new
chemical scaffolds as well as improved analogs of previously identified antimalarials. The
portfolio that has been outlined by MMV also includes antimalarials with novel targets as well
(Olliaro and Wells 2009).
The MMV portfolio includes compounds that are at the beginning stages of lead optimization,
to those that are undergoing phase III clinical trials. Of the twenty-five compounds that are
currently being developed, there is only a handful with novel properties. Some of these include
the lead optimization of an antimalarial that inhibits the parasite enzyme, dihydroorotate
dehydrogenase, DHODH, which is required for the pyrimidine synthesis (Baldwin, Michnoff et
al. 2005; Olliaro and Wells 2009). Novel molecular targets include the parasite’s mitochondria,
which is inhibited by the antimalarial 4-pyridone. 4-Pyridone is currently in phase I clinical trials
and works as a mitochondrial electron transport inhibitor (Yeates, Batchelor et al. 2008; Olliaro
and Wells 2009). The molecular targets that are currently being focused on for lead discovery
and optimizations are summarized in figure 4 from the review by Wells, et. al. One of the more
attractive targets for drug development includes the apicoplast, which is a unique organelle of
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Apicomplexa intracellular parasites. The apicoplast is a four membrane bound plastid that is
essential for P. falciparum survival in the human host as it is responsible for a number of
essential biosynthetic pathways, and would be an ideal drug target because of its presence within
the parasite alone (Kalanon and McFadden 2010). Along with novel molecular targets, the
portfolio includes new combinations of antimalarials in fixed-dose formulas (Wells, Alonso et al.
2009). Although new targets and chemical scaffolds have been identified, there is still a lack of
novelty within the portfolio. Therefore there is still an urgent need for antimalarials that work
better than those that are currently prescribed, as well as those that cost less. In order to obtain
these new drugs, there are several approaches that can be pursued.
The first is drug discovery through rational drug design. Using this approach, antimalarials are
developed by first identifying a target and validating it as being essential for parasite survival.
With the completion of the Plasmodium falciparum 23-megabase genome in 2002, rational drug
design is now a viable option in antimalarial drug discovery (Gardner, Hall et al. 2002). Once a
target has been validated, synthesis of small molecule inhibitors are developed and screened for
their potency. Target validation is also important for piggy-back drug discovery, which focuses
on using inhibitors of homologous targets in other diseases as a starting point for identifying
Plasmodium inhibitors (Nwaka and Hudson 2006). But validation of molecular targets requires
an in-depth knowledge of how the 5,000 genes identified in P. falciparum act on parasite
development and survival. Many of the genes that were identified do not contain homologous
sequences, making it difficult to identify these potential targets. With time, this dilemma will be
addressed with continued study and understanding of the parasite, but not fast enough for the
development of novel antimalarials within the next few years. In order to combat drug resistant
strains at this time, other approaches need to be taken to identify novel antimalarials. De novo
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drug discovery offers the possibility of identifying novel antimalarials from chemical libraries
that contain synthetic compounds as well as natural products . High throughput screening
methods have been developed and validated, using whole parasite assays. This allows for a rapid
and accurate account of parasite inhibition by these various chemical libraries which have been
developed through the use of biological, biochemical, and structural rationale (Nwaka and
Hudson 2006).
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Figure 4 Molecular Targets for antimalarial drug discovery (Wells, Alonso et al. 2009).
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Marine Natural Products
In the last two decades, the majority of small molecule drugs that have been developed
worldwide are analogs of compounds isolated from natural products. For example, studies on
parasitic diseases have yielded ten natural product derived drugs out of the fourteen that were
developed between 1981 and 2006 (Newman and Cragg 2007). Antimalarials are excellent
examples of small molecule drugs derived from natural products exhibiting potent activities. For
example, chloroquine and artemisinin have been used medicinally throughout history, and have
been developed into marketable drugs. Due to the ease of accessibility, most of the focus of
study for these naturally occurring products has been on terrestrial plants, with ninety-one
compounds in clinical trials in 2007 (Li and Vederas 2009).
Terrestrial plants, as stated above, have successfully yielded many drugs, but marine
biodiversity is relatively under studied. Oceans cover around seventy percent of the Earth’s
surface, and are an enormous source of biodiversity, with 34 out of the 36 phyla of life being
represented (Gul and Hamann 2005). According to one report, the estimated number of
invertebrate and algal species within the ocean is at least 200,000, but could include many more
species that have yet to be studied (Wright 2000). In 2004, alone, there were reports of at least
716 new chemical entities that were discovered with 88 new compounds that were derived from
marine natural products (Hill 2007). Although success with antiparasitic drugs from marine
natural products has been limited, the opportunities for identifying novel antimalarials has
sparked interest among researchers due to the success that has occurred within the area of anticancer therapeutics. One of the first successes was in the discovery of drug candidate from the
Caribbean sponge, Tethya crypta; which is now used to treat leukemia and non-Hodgkin’s
lymphoma patients, while other anti-tumor candidates are currently in clinical trials (Wright
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2000). In order to have success in marine natural product drug discovery, investigators must have
an understanding of how the drug discovery process works as well as access to the equipment
needed to acquire these products.
Harbor Branch Oceanographic Institute (HBOI), located in Ft. Pierce, Florida, has the
skills and equipment needed to create a unique chemical library from marine natural products.
What makes HBOI’s collection of marine specimens unique is the means by which they collect
their samples. HBOI is one of six institutions worldwide that have manned submersibles that are
able to collect marine organisms from depths as far down as 915 meters. There are three
submersibles that are equipped with arm attachments, like a scoop, claw hand, and suction
adaptor that allow them to collect specimens from the mid-water and benthic zones. Using these
vessels, HBOI has gained access to many areas within the ocean that have been unexplored for
novel compounds, including deep and shallow reefs, grass beds, caves, pilings, and even
shipwrecks, as well as other areas. Between its inception in 1984 and 2000, HBOI’s effort to
identify bioactive components has yielded a collection of 20,000 marine invertebrate and algal
species (Figure 5). These include a majority of sponges, but represent a diverse selection of
phylums found within the marine ecosystem. Once the specimens are collected, they are stored in
ethanol and are processed and enriched at HBOI and other partnering academic and industrial
institutions (Wright 2000).
Some of the successes that HBOI have had include specimens collected from sponges of
the genus Spongosorites, which are most often found with gastropod molluscs. This sponge has
been shown to contain many bioactive compounds, one of which, Topsentins, that has been
studied for its anti-inflammatory properties. Topsentins are bis(indole) alkaloids and are planar
in nature, which would allow for them to be synthesized at a relatively low cost, making the
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product less expensive for consumers. Topsentin and bromotopsentin were first to be isolated,
while similar compounds have been isolated by HBOI, and include Nortopsentin A-C,
dragmacidin D, 2,2-bis(6’-bromo-indole-3’-yl)ethyl amine. Another compound that has shown
promise for HBOI is Discodermilide, which was isolated from Lithistid sponges. The activity of
this compound was first thought to act as a immune suppressant, but it has also been shown to
have antitumor properties by acting on tubulin polymerization (Wright 2000). HBOI has also had
success with other marine specimens as well, and is currently continuing their research to
investigate other areas of therapeutics (Wright 2000).
Our laboratory partnered with HBOI to identify potential novel antimalarials from marine
natural products. During this investigation our aim is to screen marine natural products from
HBOI’s peak fraction library. This library contains a diverse amount of crude extracts that
exhibit inhibition on a panel of tumor cell lines by less than or equal to 40% at 5 g/ml. The
fractions within the peak library are also highly enriched and have been separated through the
use of medium pressure liquid chromatography, reverse phase high pressure liquid
chromatography along with UV index reading. According to the investigators at HBOI, nuisance
compounds can be eliminated based on the observation that many small molecule drugs have a
UV chromophore. The elimination of nuisance compounds allows us to avoid the screening of
inactive fractions, which will in turn reduce the cost of screening, and result in more promising
results.
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Figure 5 Distribution of Organisms in the HBOI Repository by Phylum or Division (Wright
2000)
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CHAPTER TWO: MATERIALS AND METHODS
HBOI Peak Fraction Library
We received fractions from HBOI in a 96 well round bottom plate on ice. The plates
contained 200 g of each fraction in the wells. Plates were spun down at 4°C at a speed of 1500
rpm (513 x g) for 5 minutes. After the compounds were spun down, 200 l of ethanol (200
proof) was added to each well using the epMotion 5070. The plates were then shaken at 4°C for
1 hour to ensure that they were properly mixed. They were then stored at -80°C. Dilutions of the
fractions were prepared in ethanol (1:10 and 1:100) and stored at -80°C until they were assayed.
P. falciparum Culture
Two parasite strains were cultured for the duration of this study. The strains used were a
chloroquine sensitive strain, 3D7 (ChqS, PyrS, MefS, ArtS), and a chloroquine resistant strain,
Dd2 (ChqR, PyrR, MefR, ArtS). These strains were cultured at 37°C in a humidified environment
consisting of 5% CO2, which has been shown to be an adequate gas supply for P. falciparum
growth (Radfar, Mendez et al. 2009) . The standard culture media used for maintenance was
RP0.5A media (1X RPMI 1640 with L-glutamine supplemented with 0.2% (w/v) dextrose, 15
mg/L hypoxanthine, 25 g/ml gentamycin, 25 mM HEPES, 0.2% NaHCO3 (w/v), 0.5% (w/v)
Albumax.). Whole, A+ blood was obtained from the Florida Blood Bank. The blood was washed
in 1X RPMI-1640 and the buffy coat was removed. The blood was then diluted to 50% RBCs
with phenol red-free RP0.5A culture media. Slides were made every day to assess the
parasitemia and stage of growth before splitting the culture to a lower parasitemia. Slides were
stained using Wright’s eosin methylene blue solution and buffer, which gives comparable results
to Giemsa stain (Radfar, Mendez et al. 2009).
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P. falciparum Synchronization
Parasites were synchronized by two different methods. The first method is a modified
version of the protocol described by Lambros and Vanderberg (Lambros and Vanderberg 1979).
Cells were synchronized using 5% D-sorbitol which lyses cells in trophozoite and schizont stage.
The culture was also synchronized by a gradient method using Percoll solution (65% Percoll in
5X RPMI). Percoll synchronization utilizes a gradient method to distinguish between schizont
stage parasites and earlier stage and uninfected RBCs (Saul, Myler et al. 1982; Dluzewski, Ling
et al. 1984). Infected RBCs are evaluated to ensure that a majority of the parasite culture is in the
schizont stage. Culture is then prepared in a 20% cell suspension in sterile 1X RPMI and layered
onto the Percoll solution. Cells are then spun down at 2000 rpm (911.5 x g) for five minutes at
room temperature and the schizont layer is removed and placed in a new culture dish with fresh
media and blood.
Hypoxanthine Incorporation Assay
Asynchronous culture was used for the [3H]-hypoxanthine incorporation and SYBR
Green-I based assays. During the [3H]-Hypoxanthine incorporation assay, culture was added to a
96 well clear plate at a 1% parasitemia and 2% hematocrit. The media used during this assay was
RP0.5A with low hypoxanthine, 2.5 mg/L hypoxanthine. The culture was then supplemented
with [3H]-Hypoxanthine at a concentration of 5 Ci/mL, and then 100 l of the radioactive
culture was added to each well. The culture was then incubated with the HBOI peak fractions at
the appropriate concentrations for 72 hours, enough time for the parasites to complete 1.5 life
cycles. The cells were then harvested using the TOMTEC cell harvester onto a glass fiber mat.
Infected RBC was lysed by freezing before the labeled nucleic acid was deposited on the glass
fiber mat. Each of the squares, corresponding to individual culture wells, on the mat were then
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cut and placed into individual scintillation vials and suspended in ScintiVerse BD cocktail from
Fischer Scientific. The vials were then read on the scintillation counter to obtain the amount of
radioactivity present within each well.
SYBR Green-I Fluorescence Assay
SYBR Green-I based fluorescence assay were performed in a 96 well plate
format. HBOI fractions, at their desired concentrations, were incubated with 100 l of culture at
a 1% parasitemia and a 2% hematocrit. Culture was added to each well using the epMotion 5070
liquid handler. The plates were then incubated for 72 hrs at the standard gas and temperature
conditions. Once the 72 hour incubation was completed, the parasite culture was frozen at -80°C,
thawed, and lysed with a 1X SYBR Green-I dye containing lysis buffer (20 mM Tris (pH 7.5), 5
mM EDTA, 0.008% Saponin (wt/vol), 0.08% TritonX-100 (vol/vol)). The plates were next
incubated at 37°C for 30 minutes, and then read on Wallac plate reader Victor2- 1420 multilabel
counter. Results were analyzed using Microsoft Excel and GraphPad Prism software. The
controls used in the [3H]-hypoxanthine incorporation assay as well as the SYBR Green-I
fluorescence assay were 1 M Chloroquine and 1 M Artemisinin for 3D7 and Dd2 lines,
respectively.
Assay Accuracy and Sensitivity
Originally developed to validate hits from the high throughput screening of chemical
libraries, the Z-factor is defined as the screening window coefficient. The Z-factor is calculated
by Z’= 1- 3((c+ - c-)/ |c+ - c-|). The value represents the degree of sensitivity and accuracy of
the assay being used. When the Z-factor is equal to 1, the assay is said to be ideal. A value below
1, but greater than 0.5 represents an excellent assay. Whereas values below 0.5 indicates that the
assay is not accurate, and another method should be identified for further screening (Zhang,
28

Chung et al. 1999). The mean values and standard deviations were calculated using Microsoft
Excel software.
Mammalian Cell Toxicity Assay
The NIH 3T3 human fibroblast cell line was used in the presence of HBOI peak fractions
to determine the selectivity index. Fibroblasts were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 1 mM sodium bicarbonate, 1X Pen-strep, and 10% heat
inactivated fetal bovine serum (FBS). Cells were incubated at 37°C in a humidified, 5% CO2,
environment. In order to maintain the cell lines, cells were seeded into a new dish once they
reached 90% confluency. During this step, the cells were washed with 1X DPBS, followed by
treatment with 1X Trypsin-EDTA for thirty seconds and a two minute incubation at 37°C after
the liquid was removed to release the cells from the surface of the dish. The dish was then placed
at 37°C and incubated for two minutes before they were resuspended in DMEM and added to a
fresh culture flask.
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) Cell Viability
Assay, was performed following an adapted protocol outlined by Mosmann (Mosmann 1983). To
begin, viable cells were counted using the trypan blue (Sigma-Aldrich) exclusion method. Cells
were then counted on a hemacytometer, and diluted to 15,000 viable cells per 50 l of phenol
red-free culture media. Cells were then pipetted into a 96-well clear plate and incubated for 1012 hours to allow the cells to reattach to the surface of the plate. While the cells were incubating,
the selected peak fractions were pipetted out into microcentrifuge tubes at the appropriate
concentrations. The ethanol was allowed to evaporate out of each tube. Once the ethanol had
evaporated out of each tube, the fraction was resuspended in phenol red-free DMEM. Before the
fractions were added, their UV absorbance was measured on the Nanodrop 1000. After the tube
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was empty and the contents were added to each well, the same volume of ethanol (200 proof)
was added to the microcentrifuge tube. The UV absorbance was then read again to ensure that
the all of the compound was removed from the tube. The plates were then incubated with the
fractions at 37°C for 15 hours. After 13 hours of incubation, 60 ng/l digitonin was added to the
control wells, and the plate was placed back in the 37°C incubator. Once the cells completed
their 15 hour incubation, 20 l of MTT reagent (5 mg/ml) was gently added to each well. The
plate was incubated for an additional 4 hours at 37°C. Without disturbing the bottom of the well,
the MTT reagent and media were removed from the wells, and 150 l of MTT Solvent
(Isopropanol, 4 mM HCL, 0.1% Nonidet P-40) was added to each well. The plate was then
covered with aluminum foil and shaken on the Eppendorf MixMate for 15 minutes. The
absorbance was then read on the Tecan Infinite M200 Plate reader at 590 nm, with a reference
reading at 700 nm. Results were analyzed using Microsoft excel and Graph Pad Prism Software.
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CHAPTER THREE: SCREENING OF HBOI PEAK FRACTION LIBRARY
To identify new leads for malaria therapy we have screened HBOI’s peak fraction library
collection. A rapid turnaround time is needed to efficiently screen these libraries and is essential
to the success of this project. The current standard for screening new potential antimalarials in
Plasmodium falciparum species is through the use of a [3H]-hypoxanthine incorporation assay.
This method has proven to be a reliable screening method, but needs radioactive material for the
assay. This results in a lower assay throughput, and a higher cost of around $33.00 per assay
(Abiodun, Gbotosho et al. 2010). An alternative method utilizes the DNA intercalating
fluorescent dye SYBR Green-I to stain parasite DNA within mature RBCs. SYBR Green-I dye
has an affinity for staining double stranded DNA as opposed to ssDNA and RNA(Johnson,
Dennull et al. 2007) . This allows it to be a useful tool in the screening process because the only
DNA that will be monitored is that of the parasite present within the infected RBC (iRBC). The
usefulness of the SYBR Green-I assay is that it can be developed into a 96-, 384-, or 1536- well
format. For example, recently, libraries of 1.7 million compounds have been screened in a 1536
well format and yielded around17,000 potent inhibitors of Plasmodium (Plouffe, Brinker et al.
2008). The use of SYBR Green-I as a primary screening tool has been validated by many
laboratories, and has become a reliable, low cost, around $1.75 per assay (Abiodun, Gbotosho et
al. 2010), method in high throughput P. falciparum screening (Bennett, Paguio et al. 2004;
Johnson, Dennull et al. 2007; Rason, Randriantsoa et al. 2008; Co, Dennull et al. 2009). We
tested both the [3H]-hypoxanthine and SYBR Green-I assay methods before engaging into a
large scale screening of the HBOI peak fraction library in a 96-well plate format to identify novel
antimalarials.
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Validation of SYBR Green-I Fluorescence based assay
[3H]-Hypoxanthine incorporation assays have become an extremely reliable method for
in vitro growth assessment in P. falciparum culture. This is due to the fact that Plasmodium spp.
of parasites are unable to synthesize purine rings, relying on a salvage pathway instead for de
novo synthesis (Downie, Kirk et al. 2008).In order to compare the [3H]-Hypoxanthine
incorporation assay with the SYBR Green-I fluorescence based assay, we analyzed the Z-factors
and quantity of hits identified. Our results show that the Z-factors for both assays were above the
required 0.5 (Zhang, Chung et al. 1999), with the [3H]-Hypoxanthine incorporation assay having
a Z-factor of 0.69, and the SYBR Green-I Fluorescence based assay having a Z-factor of 0.52.
Although the [3H]-Hypoxanthine incorporation assay had a higher Z-factor, both assays
identified the same initial hits from the peak fraction library having similar percent inhibition
levels. Based on this result, we decided to continue screening using the SYBR Green-I (SG)
fluorescence based assays for our screening because of the ease of using a non-radioactive assay.
Primary Screening of Marine Natural Products
Once the reliability of the SG assay was established, the remaining HBOI Peak library
plates were screened against the chloroquine sensitive strain of P. falciparum 3D7 strain. Each of
the thirty-three HBOI peak fraction library plates were plated at a concentration of 10 g/mL,
and incubated with 3D7 P. falciparum culture for 72 hours. The duration of incubation is enough
to allow the parasites to complete one and half life cycles. This will also ensure that the fractions
will have an opportunity to inhibit the growth during every stage of development, as well during
the invasion of the parasite into the RBC at the beginning of the next developmental cycle.
During the primary screening we identified a total of 253 fractions out of 2,830 that
inhibited parasite growth at greater than or equal to 70% of the controls. This represented an
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initial hit rate of 8.94%, with an average Z-factor of 0.77 (Table 1). From the positive fractions,
we selected the two best inhibiting fractions from each species of marine organisms for further
analysis. Due to the rate at which new plates were received, primary focus was placed on the
MNP plates Mal004 through Mal011. Mal004 through Mal011 were screened for their percent
inhibition at 5 g/mL (Table 2), and those that were found to inhibit growth at greater than or
equal to 70% of the control were selected as preliminary hits. Hits are generally defined as those
products whose IC50 values are less than 0.2 g/mL of pure compound in P. falciparum. The
selection criteria for our screening were adjusted because fractions, although enriched, are likely
to contain multiple chemical compounds. Therefore, fractions were selected based on the criteria
stated above with the initial screening criteria being left up to the discretion of the primary
investigators (Fidock, Rosenthal et al. 2004; Nwaka and Hudson 2006).
The IC50 value for each of the selected fractions was determined using the SG assay to
measure parasite growth. The average Z-factor calculated for these assays were 0.76, indicating
that the assays were statistically reliable (Table 3). Table 3 represents the fractions whose IC50
values were below 5 g/mL, with fifteen of the thirty-three fraction’s IC50 values being less than
1 g/ml. Dose response graphs representing the potency of a few selected peak fractions are
shown in figure 6. The four fractions represented are from four different marine organisms
whose IC50 values were below 1.5 g/mL. The fractions that had an IC50 value less than 5 g/mL
were selected to further investigate their potency against the chloroquine resistant strain of P.
falciparum.
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SYBR Green at
Plate ID

SYBR Green at
Plate ID

10 g/ml

10 g/ml

Mal 004

6 fractions

Mal 005

3 fractions

Mal 006

3 fractions

Mal 007

5 fractions

Mal 008

5 fractions

Mal 009

9 fractions

Mal010

18 fractions

Mal011

29 fractions

Mal012

9 fractions

Mal013

11 fractions

Mal014

5 fractions

Mal015

21 fractions

Mal016

9 fractions

Mal017

12 fractions

Mal018

17 fractions

Mal019

4 fractions

Mal020

13 fractions

Mal021

9 fractions

Mal022

6 fractions

Mal023

4 fractions

Mal024

7 fractions

Mal025

1 fraction

Mal026

4 fractions

Mal027

7 fractions

Mal028

5 fractions

Mal029

6 fractions

Mal030

7 fractions

Mal031

6 fractions

Mal032

6 fractions

Mal033

6 fractions

Table 1 The number of peak fractions inhibiting chloroquine sensitive 3D7 growth. Each fraction
that was identified as a preliminary hit based on the percent inhibition compared to 1 M
chloroquine.
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Unique I.D

% Inhibition
at 5g/ml

Unique
I.D

% Inhibition
at 5g/ml

Unique
I.D

% Inhibition
at 5g/ml

4.A06

83.0

7.G05

111.0

9.G07

96.0

4.A10

80.0

7.G11

108.0

9.H09

107.0

4.B03

86.0

7.H01

104.0

10.A02

104.0

4.B07

84.0

8. E04

80.0

10.C10

98.0

4.H01

79.0

8. E06

90.0

10.C11

96.0

5.B05

88.0

8. E08

106.0

10.D08

95.0

5.G06

103.0

8.F01

88.0

10.D09

83.0

5.G07

109.0

8.F07

83.0

11.A08

87.0

6.D04

78.0

9.C06

95.0

11.B03

92.0

6.H04

84.0

9.C07

90.0

11.H01

96.0

7.C08

96.0

9.G04

95.0

11.H02

98.0

Table 2 Inhibiting peak fractions from plates Mal004 through Mal011. Inhibition was measured
in comparison with the inhibition of parasite growth by 1 M chloroquine in chloroquine
sensitive parasites.
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Unique I.D

IC50 g/ml

Unique I.D

IC50 g/ml

Unique I.D

IC50 g/ml

4.A06

1.5

7.G05

0.4

9.G07

0.2

4.A10

2.2

7.G11

< 0.25

9.H09

0.5

4.B03

2.4

7.H01

1.7

10.A02

2.0

4.B07

0.9

8. E04

1.3

10.C10

2.2

4.H01

0.9

8. E06

1.5

10.C11

0.2

5.B05

1.2

8. E08

1.8

10.D08

< 0.2

5.G06

1.3

8.F01

0.6

10.D09

1.1

5.G07

4.8

8.F07

<0.25

11.A08

1.1

6.D04

0.8

9.C06

<0.25

11.B03

0.7

6.H04

1.4

9.C07

<0.25

11.H01

1.3

7.C08

4.6

9.G04

2.5

11.H02

0.8

Table 3 IC50 values of inhibiting peak fractions in 3D7. The IC50 values for the preliminary hits
were determined using the SG assay with 1 M chloroquine as a control for parasite growth
inhibition.
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Figure 6 Dose-response curves were used to evaluate the IC50 value of preliminary hits. Percent
parasitemia was determined by the comparison of parasite growth in treated parasites versus
those treated with 1 M chloroquine, and those that remained untreated.
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Screening of Peak Fractions against Drug Resistant P. falciparum
Any effort to find a novel cure for malaria must demonstrate that the active compound is
also equally effective against chloroquine resistant strains. To address this issue, peak fractions
were also screened against Dd2, the laboratory chloroquine resistant strain (ChqR, PyrR, MefR,
ArtS). This allows us to predict which of the fractions will be more useful against drug resistant
malaria.
We determined the percent inhibition at 5 g/mL (Table 4) and IC50 values (Table 5)
against the chloroquine resistant strain. Our initial screening against Dd2 at 5 g/mL, showed
that 82% of the peak fractions that were active against the sensitive 3D7 strain inhibited Dd2
growth at greater than or equal to 70% of the control, 1 M artemisinin. The average Z-factor
from these screening efforts was 0.75, making these results statistically reliable. The IC50 values
of the inhibitory peak fractions were determined using the Dd2 strain. Among the thirty-three
inhibitory fractions, twenty five fractions exhibited IC50 values less than 5 g/mL against
chloroquine sensitive and resistant strains, 3D7 and Dd2 respectively. Of the twenty-five that
were found to be inhibitory, the fractions derived from four species, Axinellida, Spirastrella sp.,
Gastropoda Aplysia sp., and Peysonellia, were found to be the most potent. The peak fractions
from these species had IC50 values less than, or equal to, 1.1g/mL (Figure 7). These fractions
were selected for further investigation of their potential cytotoxic properties in human fibroblast
cells.
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Unique I.D

%Inhibition
at 5 g/ml

Unique I.D

%Inhibition
at 5 g/ml

Unique I.D

%Inhibition
at 5 g/ml

4.A06

103.9

7.G05

103.3

9.G07

99.0

4.A10

74.9

7.G11

105.0

9.H09

94.7

4.B03

77.5

7.H01*

65.4

10.A02

99.9

4.B07

76.6

8. E04*

43.8

10.C10

105.9

4.H01

101.9

8. E06

95.3

10.C11

101.0

5.B05

69.7*

8. E08

89.7

10.D08

99.2

5.G06

106.0

8.F01

70.2

10.D09

82.7

5.G07

102.3

8.F07

72.1

11.A08

91.7

6.D04

79.7

9.C06*

49.0

11.B03

95.5

6.H04

101.5

9.C07*

55.9

11.H01

104.0

7.C08

10.4*

9.G04

99.4

11.H02

107.8

Table 4 Inhibition of chloroquine resistant parasites. A Dd2 parasite cell line was used to screen
the preliminary hits for their ability to inhibit compared to 1 M artemisinin. Inhibition of Dd2
percent inhibition was then compared to 3D7 percent inhibition to predict which fractions had
the potential to work in resistant strains of the parasite.
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Unique I.D

IC50 g/ml

Unique I.D

IC50 g/ml

Unique I.D

IC50 g/ml

4.A06

1.3

7.G11

0.5

10.A02

1.1

4.A10

2.3

8. E06

4.3

10.C10

0.7

4.B07

1.0

8. E08

2.4

10.C11

0.2

4.H01

4.8

8.F01

4.9

10.D08

0.1

5.G06

4.2

8.F07

4.9

10.D09

<0.2

5.G07

3.1

9.G04

2.0

11.A08

2.5

6.H04

2.1

9.G07

0.8

11.B03

2.6

7.G05

1.5

9.H09

4.6

11.H01

1.1

11.H02

0.8

Table 5 IC50 values of inhibiting peak fractions in Dd2. The IC50 values were determined using
the SG assay with 1 M artemisinin as a control for inhibition of chloroquine resistant parasite
growth.
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Figure 7 Dose-response curves were used to evaluate the potency of preliminary hits against
chloroquine resistant parasites. Percent parasitemia was determined by the comparison of
parasite growth in treated parasites versus those treated with 1 M artemisinin, and those that
remained untreated.
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CHAPTER FOUR: MTT CELL VIABILITY ASSAY
One of the most significant issues in drug discovery research is the rate of failure. For
every ten compounds that make it to phase I clinical trials there is only one that can be marketed
as a drug. Reasons for failure are in many circumstances related to the safety of a drug in patients
(Bass, Cartwright et al. 2009). Therefore, an important criterion for selecting a bioactive fraction
for lead discovery is to determine its selectivity index. As a potential antimalarial, the positive
fraction we have identified must show that it inhibits the growth of P. falciparum without
causing harm to the human host. In order to eliminate potential toxicity issues, researchers have
begun to use a variety of screening techniques to predict the in vivo selectivity profile of lead
compounds (Bass, Cartwright et al. 2009). Using these results, the most selective and bioactive
compounds are used for further studies. Two commonly used cell viability assays were used to
screen against active peak fractions to eliminate those that could potentially be cytotoxic. One of
the first attempts to study cell viability was performed using the MultiTox-Glo Cytotoxicity
assay commercially available from Promega. Protease markers are identified in viable cells and
dead cells using two different protease substrates which become fluorescent or luminescent when
interacting with its protease marker (Niles, Moravec et al. 2007). Viable cells are measured
based on the amount of substrate that interacted with the Cathepsin-C, a viable cell protease,
while dead cells are measured by the substrate which interacted with Tripeptidyl peptidase II, an
active protease during apoptosis (Niles, Moravec et al. 2007). Ideally, this method would have
given results that inversely corresponded to one another. We performed the assay according to
the protocol outlined by Promega with NIH 3T3 fibroblast cells and found that the results were
not reproducible; therefore we began to look for alternative methods for evaluating cell viability.
Rather than looking at specific markers for protease activity, we chose to use the MTT assay
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which measures cellular metabolism. Tetrazolium dyes are reduced by mitochondrial
dehydrogenases present in living cells to a blue formazan crystal. Using this method, crystals are
dissolved in an isopropanol based solvent, and the absorbance corresponds to the amount of
living cells present within each well (Mosmann 1983). This assay is very reliable, and when
compared to the MultiTox-Glo Cytotoxicity assay (around $180.00 per 96-well plate assay), is
less expensive. For those reasons, we chose to use the MTT assay with a human fibroblast cell
line, NIH 3T3 to study the selectivity index of potent MNPs. The NIH 3T3 cell line has been
successful in previous cell viability assays (Theiszova, Jantova et al. 2005).
HBOI Peak Fraction Library Selected Fractions
The peak fractions from the top four inhibiting species identified during the initial
screening of the HBOI peak fraction library plates Mal004 through Mal011 were screened
against NIH 3T3 fibroblast cells to assess their cytotoxic properties and determine their
selectivity index, a comparison of peak fraction IC50 values between Plasmodium and fibroblast
cultures. Cells were incubated with each peak fraction for 15 hours at 3 different concentrations,
1 g/mL, 10 g/mL, and 100 g/mL (Figure 8). These graphs showed that five out of the eight
fractions exhibited selectivity indices ten, or greater. Three of the fractions, 10.D08, 11.H01, and
11.H02, were found to exhibit cytotoxic properties against the fibroblast cells, with selectivity
indices below ten. Knowing their potential cytotoxic risk, these fractions will be eliminated in
future studies of these MNPs.
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Figure 8 Toxicity profiles of select MNPs exhibit promising selectivity indices. Prediction of in
vivo selectivity index was performed by comparison of inhibition in the presence of selected
peak fractions compared to cells that were untreated and those that were treated with digitonin.
Peak fractions that had a selectivity index greater than 10 were determined to be promising for
future studies.

45

CHAPTER FIVE: NORTOPSENTIN A AS A NOVEL ANTIMALARIAL
Nortopsentin A inhibition of Plasmodium falciparum growth
HBOI’s peak fraction library consists of enriched fractions that contain more than one
compound. The separation of single compounds requires further purification steps which are
performed at HBOI. Once the fraction has been purified and the chemical structure has been
identified, the information is sent to our lab where we screen the fraction again for its molar IC50
value in chloroquine sensitive and chloroquine resistant strains. Previous screening of the MNP
peak fraction library revealed fractions from the Spongosorite species of sponges to be potent
inhibitors of chloroquine sensitive parasite growth. Upon purification of extract from this species
of sponge, Nortopsentin A was one of the chemical scaffolds identified (Figure 9). Nortopsentin
A has been identified and screened against a variety of tumor cell line, as well as screened for its
anti-inflammatory properties (Wright 2000; Diana, Carbone et al. 2007). When searching
through the literature, it was found that Nortopsentin A had not yet been identified as an
antimalarial, making it an attractive compound to continue for further studies.
Using the SG assay, we determined the IC50 value for Nortopsentin A in both 3D7 and
Dd2. These values were identical in both strains of P. falciparum screened (Figure 10). Both
values were found to be 1.6 M, which is within the accepted antimalarial standard IC50 value
range of 1 to 5 M (Fidock, Rosenthal et al. 2004). The Z-factors for both assays were 0.95,
making these results statistically reliable.
Nortopsentin A Cell Viability Assay
As with the aforementioned cell viability assays, an important step in the process of
discovering a novel antimalarial, is the determination of the selectivity index to eliminate
possible failures during in vivo studies. In order to ascertain this data, the compound was tested
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at 0.5X, 1X, 10X, 100X, and 200X the IC50 value calculated for its activity against P. falciparum
(Figure 11). Results from this assay indicated that Nortopsentin A exhibited cytotoxicity at high
concentrations in the fibroblast cells, with its IC50 value in fibroblast cells being 15 M, a
selectivity index of 9.4.
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Figure 9 Chemical structure for Nortopsentin A.
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Figure 10 Inhibition of chloroquine sensitive and chloroquine resistant parasite growth by
Nortopsentin A. Dose-dependent inhibition was performed beginning at 10 M concentration
and decreasing to 0.2 M. The assay was performed using the 1 M concentrations of
chloroquine and artemisinin as positive controls.

49

Figure 11 Toxicity in the presence of Nortopsentin A. Toxicity was evaluated at concentrations
of 0.5X, 1X, 10X, 100X, and 200X of the parasite IC50 value, using the absence of drug
treatment and digitonin treatment as positive and negative controls.
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Effect of Nortopsentin A on Parasite Development
In order to better understand the mechanism of action on Plasmodium, 3D7 culture was
incubated with 3 M Nortopsentin A and time points were collected. Giemsa stained slides were
made at 16 hours, 32 hours, and 48 hours. The parasite stages in the presence of Nortopsentin A
and those without any inhibitor were then compared using a light microscope (Figure 12). Our
results indicated that Nortopsentin A inhibited parasite growth at this concentration and acted on
the early stage of parasite development. The parasites in the absence of inhibitor progressed
through each stage of development from ring to schizont to re-infection. In contrast, the
development of the parasite in the presence of Nortopsentin A at 3M was blocked at the late
ring/early trophozoite stage.
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Figure 12 Development of chloroquine sensitive parasites in the presence of 3 M Nortopsentin
A. Images of the parasite culture were taken at 0 hours, 16 hours, 32 hours, and 48 hours. The
stage of growth was observed in both treated and untreated cells to determine the effect of
Nortopsentin A on parasite development.
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CHAPTER SIX: DISCUSSION
Plasmodium falciparum is the deadliest form of parasite that causes malaria infection.
The emergence of drug resistant strains has led to a resurgence of drug discovery research in an
effort to find novel, safe, effective, and inexpensive therapies and prophylactics. Using the peak
fraction library supplied by HBOI, we have successfully screened over 2,000 marine natural
products for their antimalarial activity. With the use of the SYBR Green-I fluorescence based
assay, we have screened these fractions quickly and accurately, without the inconvenience of
using radioactive material. Using this assay we found there to be a nine percent hit rate, which is
higher than the hit rate of 0.3% and 0.001% for the average natural product and synthetic library
(Li and Vederas 2009). Screening of HBOI’s peak fraction library has led to many options for
future studies. Identifying a larger percentage of biologically diverse preliminary hits will
hopefully lead to a higher rate of success later in the drug discovery pipeline.
Peak fractions that we screened represented a diverse number of marine organisms,
around 122 different species. The organisms that are present within the library are unrelated to
many terrestrial plants, and therefore hold the potential for containing novel chemical scaffolding
for drug discovery (Gul and Hamann 2005). Some of the more promising species from which
fractions originated included sponges, Axinellida and Spirastrellla, algae, Peysonellia, and a
species of mollusks, Gastropoda Aplysia. Two of the more potent and least cytotoxic fractions
originated from Spirastrella. It has been previously reported that this sponge is capable of
producing secondary metabolites that act as antimitotic and antiviral drugs (Garg and Agrawal
1995; Williams, Roberge et al. 2003). One of the most potent fractions screened was isolated
from the species Peysonellia, an alga species, and was previously reported to act as an anticancer
drug (Crews, Gerwick et al. 2003). As described, these are only two of the 122 species that we
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identified as preliminary hits. Having potent antimalarial activity and promising cytotoxic
profile, purification followed by structure identification of these fractions will allow us to
identify novel antimalarials.
Only one pure compound, Nortopsentin A, was analyzed in this study. This compound
was isolated from a species of sponges, Spongosorites, and is a potent inhibitor of drug
susceptible and resistant P. falciparum growth, with around a tenfold difference between the IC50
values in NIH 3T3 fibroblast cells and P. falciparum culture. It is a bis(indolyl) alkaloid which
has been found to be within a group of sponge metabolites that are recognized for their antiinflammatory, antimicrobial, antiviral, and antitumor activities at low IC50 values (Diana,
Carbone et al. 2007). With the discovery of its antimalarial activity, we wanted to determine the
potential mechanism of action for this compound and were able to clearly see that not only is the
parasite growth inhibited, but the development of the parasite into more mature stages is halted
between late ring and early trophozoite stage (Figure 10). Previous studies of alkaloids have
shown that they can act as DNA intercalating agents and halt DNA synthesis (Martinez and
Chacon-Garcia 2005). Our results correlate well with the known mechanism of Nortopsentin A
as DNA synthesis occurs during the trophozoite stage of the asexual, erythrocytic growth. If
Nortopsentin A binds to DNA during ring stage of development, DNA synthesis in trophozoite
stage will likely be inhibited, and progression of the cell cycle would cease. Further studies are
needed to fully understand the mechanism by which Nortopsentin A inhibits the growth of P.
falciparum. Although Nortopsentin A is the most promising hit we have identified, its current
profile, shows that it is a potent inhibitor of P. falciparum, but the projected selectivity index
needs to be increased to greater than 100 by structural modifications in order to be considered as
a candidate for lead optimization (Fidock, Rosenthal et al. 2004).
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Marketing a new antimalarial requires that a compound be potent against the parasite,
along with having favorable selectivity and pharmacological properties. Structural modifications
are necessary to obtain a marketable product, and require the assistance of medicinal chemist to
view the structural properties and create a series of modified structures. For Nortopsentin A,
modified structures have already been synthesized for other therapeutic purposes. Some of these
modifications include the bromination of the R group in Nortopsentin’s structure. The addition of
this group has been shown to decrease activity in a leukemia cell line, P-388 (Gul and Hamann
2005). When analyzing the potency of these modified structures, the pharmacological properties
of the compound must also be considered. Structural modifications need to be made to ensure
that Nortopsentin A is soluble, that it is not metabolized quickly, and that it does not bind to
plasma. In order ascertain this information, an ADME (absorption, distribution, metabolism, and
excretion) profile of the compound can be developed through a series of laboratory experiments.
With these modified structures already synthesized, we can compare the activities, toxicity, and
pharmacological properties, and select the most attractive structure for lead discovery.
Previous studies on the use of MNPs from HBOI were focused on other therapeutic areas
of research such as antitumor, antiviral, and antimicrobial agents; however, their ability to collect
fractions from novel sources and perform structural identification has allowed us to create a
library of potential, novel antimalarial leads. Here, we have shown that through the screening of
a novel peak fraction library, we can identify potential lead compounds..
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